Evidence map›Paper›PMID 42814516›Full record

ArticleChemistry & biodiversity2026

First Synthesis of Shimobashiric Acid C With Acetonide as the Catechol Protecting Group.

Ruwen Li, Zhe Zhang, Pengshu Xu, Lin Zhou, Lei Chen, Zhongqiang Liu

Abstract read
In one paragraph

Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruwen LiSchool of Pharmaceutical Sciences, Hainan University, Haikou, Hainan Province, P.R. China.ORCID https://orcid.org/0009-0008-6914-6557
Zhe ZhangSchool of Pharmaceutical Sciences, Hainan University, Haikou, Hainan Province, P.R. China.
Pengshu XuSchool of Pharmaceutical Sciences, Hainan University, Haikou, Hainan Province, P.R. China.
Lin ZhouSchool of Pharmaceutical Sciences, Hainan University, Haikou, Hainan Province, P.R. China.
Lei ChenSchool of Pharmaceutical Sciences, Hainan University, Haikou, Hainan Province, P.R. China.
Zhongqiang LiuSchool of Pharmaceutical Sciences, Hainan University, Haikou, Hainan Province, P.R. China.

Funding

Hainan Provincial Natural Science Foundation 821RC533National Natural Science Foundation of China 22167012
6 · The paper itself

Abstract

Shimobashiric acid C (SBA-C) shows excellent hyaluronidase inhibition but its natural isolation yield is only 0.0092 %. We report its first synthesis via a convergent seven-step route from caffeic and rosmarinic acids in 35% overall yield. Direct protection of D-Danshensu (D-DSS) with 2,2-dimethoxypropane gave an isochroman; the desired acetonide-protected D-DSS building block was instead prepared from methyl rosmarinate via bis-acetonide formation followed by methanolysis. Acetonide-protected caffeic acid was synthesized and crystallized in a P-1 lattice, where linear hydrogen-bonded caffeic acid pairs pack with adjacent alkenyl bonds aligned at 3.919 Å for head-to-tail solid-state [2+2] photodimerization. Irradiation at 365 nm gave the acetonide-protected α-truxillic acid building block. The two blocks were condensed via Steglich esterification to give acetonide-protected SBA-C methyl ester. Selective deprotection of the acetonide groups was achieved with 55% trifluoroacetic acid in the presence of trace water in nearly quantitative yields. This mild deprotection caused no noticeable side reactions and may be applied to synthesis of other D-DSS-containing phenolic acids, such as salvianolic acids.

Indexed as

CyclobutanesMolecular StructureCyclobutanesacetonide protectionD‐Danshensuphotodimerizationshimobashiric acid Cα‐truxillic acid

Identifiers

PMID42814516
PMCPMC13626253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.